<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371668</url>
  </required_header>
  <id_info>
    <org_study_id>150069</org_study_id>
    <secondary_id>15-I-0069</secondary_id>
    <nct_id>NCT02371668</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model</brief_title>
  <acronym>CR6261</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Researchers want to see if a new drug reduces flu disease in people treated with this drug
      versus a placebo. The drug has an antibody that may help the immune system fight the flu.
      Placebo is only sugar and water. All participants will get the flu virus. They may or may not
      develop flu symptoms.

      Objective:

      - To see if the drug CR6261 reduces flu disease in people treated with this drug versus a
      placebo.

      Eligibility:

      - Healthy nonsmokers ages 18 45.

      Design:

        -  Participants will be screened under a separate protocol.

        -  Participants must use contraception or abstinence for several weeks before and after the
           study. They must have no alcohol for 1 day before each visit. Any medicine must be
           approved by the study doctor until after follow-up.

        -  Participants will stay in a hospital isolation unit for at least 10 days.

        -  They will have:

        -  Medical history

        -  Physical exam

        -  Blood and urine tests

        -  Heart and lung test

        -  Tests for drugs and alcohol

        -  Throughout their stay, participants will:

        -  Be closely watched by a medical team

        -  Have nasal washes and swabs several times a day

        -  Participants will have the flu virus sprayed in each nostril.

        -  The next day, participants will get either study drug or placebo through a soft plastic
           tube placed in a vein by needle. It will take 2 hours. They will not know which they
           get.

        -  Participants can go home after 10 days if they test negative for the flu 2 days in a
           row.

        -  Participants will have daily questionnaires at home and 2 follow-up visits over 2
           months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The high morbidity and mortality associated with both pandemic and seasonal influenza and the
      threat of new potentially pandemic strains emerging makes influenza an important infectious
      disease and public health problem. Mean annual estimates of influenza deaths due to seasonal
      influenza alone attributes up to 49,000 deaths in the US and 250,000 to 500,000 deaths in
      industrialized countries to influenza. Pandemics can have an even more devastating effect.
      Public health agencies must continue to be prepared by making attempts to reduce the public
      health impact of this important virus.

      In the realm of influenza therapeutics, antiviral drugs are currently used to treat influenza
      infection in those who fail to be protected by current vaccines or those who do not receive a
      vaccine. Currently, only two classes of antivirals are FDA approved for the treatment of
      influenza A: neuraminidase inhibitors and matrix M2 channel blockers. Although these drugs
      have been shown to be effective in reducing influenza illness by 24-48 hours and reducing
      shedding in relatively healthy adults, as with vaccination, they have had limited
      effectiveness in high risk groups and those who have severe or complicated influenza
      infections. In addition, antiviral resistance has become very common in human influenza A
      viruses, as currently circulating H1N1 and H3N2 strains are resistant to the adamantane M2
      channel blockers and many cases of neuraminidase inhibitor resistance have also been reported
      with strains of both subtypes. This resistance can develop quickly and in most cases only
      requires a single amino acid change. Given these significant issues with currently available
      treatments, novel therapies for influenza are clearly needed.

      Live virus challenge studies have played a pivotal role in developing influenza therapeutics
      in the past, and they will be instrumental in the future. No novel therapeutic or
      prophylactic agent has been FDA-approved since the last influenza challenge studies ceased
      over a decade ago. In collaboration with the Crucell Vaccine Institute (part of Crucell which
      is in the Janssen family of Pharmaceutical Companies of Johnson &amp; Johnson) this protocol will
      evaluate mAb CR6261 for possible therapeutic value. Unlike the current antivirals that are
      compounds which interfere with some portion of the viral replicative cycle, this agent is a
      mAb that targets the stem of HA, neutralizing the virus by stabilizing the pre-fusion state
      and preventing the pH-dependent fusion of viral and cellular membranes. Pre-clinical data
      suggest that this mAb has good cross-protective efficacy with a variety of HA subtypes unlike
      current vaccines, making it potentially effective in the event of an emerging influenza virus
      outbreak with a novel HA subtype. In addition, the conserved nature of the HA stem region
      suggests that amino acid changes conferring resistance are much less likely. We will effort
      to demonstrate that CR6261 leads to improved outcomes compared with placebo with respect to
      the AUC of virus shedding as determined by qPCR in NP swabs in all treated subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 25, 2015</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Viral Shedding</measure>
    <time_frame>3 times a day for 10 days</time_frame>
    <description>Area under the curve (AUC) calculated from quantitative real-time RT-PCR for influenza A taken from 3 time per day nasal swab collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Influenza Infection</measure>
    <time_frame>Evaluated daily for 10 days + 8 weeks convalescent follow up</time_frame>
    <description>Percentage of participants who experienced either viral shedding or symptoms + a four fold rise in convalescent HAI titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Shedding</measure>
    <time_frame>Evaluated for up to 2 months</time_frame>
    <description>Duration in days viral shedding was detected after influenza challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Symptoms</measure>
    <time_frame>Evaluated for up to 2 months</time_frame>
    <description>Duration in days symptoms were experienced after influenza challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mild to Moderate Influenza Disease</measure>
    <time_frame>Evaluated daily for 10 days</time_frame>
    <description>Percentage of participants who experienced influenza symptoms and shedding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptoms</measure>
    <time_frame>Evaluated for up to 2 months</time_frame>
    <description>Number of unique influenza symptoms experienced after influenza challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>Evaluated daily for 10 days</time_frame>
    <description>Percentage of participants who experienced influenza symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total FLUPRO Score</measure>
    <time_frame>Evaluated from day 0 to day 8</time_frame>
    <description>Objective symptoms score from patient directed FLUPRO questionnaire (inFLUenza Patient-Reported Outcome dairy) . The FLUPRO questionnaire uses a 5-point ordinal scale, with higher scores indicating a more frequent sign or symptom. Total scores can range from 0 (symptom free) to 4 (maximum severity of symptoms). Daily scores (Day 0 - Day 8) are averaged to calculate a total score for each participant, then calculated the median total FLUPRO score for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Shedding</measure>
    <time_frame>Evaluated daily for 10 days</time_frame>
    <description>Percentage of participants who experienced influenza viral shedding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>H1N1 Influenza Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 5% dextrose (D-glucose) water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CR6261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR6261</intervention_name>
    <description>50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).</description>
    <arm_group_label>CR6261</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:

          1. Greater than or equal to 18 and less than or equal to 45 years of age.

          2. Non-smoker.

          3. Willingness to remain in isolation for the duration of viral shedding (at a minimum 10
             days) and to comply with all study requirements.

          4. A male subject is eligible for the study if he agrees to practicing abstinence or
             using a condom with spermicide plus an acceptable form of contraception (see inclusion
             criteria 5) being used by any female partner from 4 weeks before to 12 weeks after
             intranasal challenge with influenza.

          5. A female participant is eligible for this study if she is not pregnant or breast
             feeding and 1 of the following:

               -  Of nonchildbearing potential (i.e., women who have had a hysterectomy or tubal
                  ligation or are postmenopausal, as defined by no menses in greater than or equal
                  to 1 year).

               -  Of childbearing potential but agrees to practice effective contraception or
                  abstinence for 4 weeks prior to and 8 weeks after administration of the influenza
                  challenge virus. Acceptable methods of contraception include a male partner who
                  is sterile and is the sole sexual partner of the female participant or a male
                  partner who uses a condom with spermicide plus 1 or more of the following: 1)
                  implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device
                  with a documented failure rate of &lt;1%; 4) oral contraceptives; and 5) double
                  barrier method including diaphragm.

          6. Willing to have samples stored for future research.

          7. Prechallenge serum HAI titer against the challenge virus less than or equal to 1:10
             within 60 days of admission for the study.

          8. HIV uninfected confirmed by testing within 60 days of admission for the study.

          9. Agrees to abstain from alcohol intake 24 hours before admission on Day -1, during the
             inpatient period of the study, and 24 hours prior to all other outpatient clinic
             visits.

         10. Agrees to not use over-the-counter medications (including aspirin, decongestants,
             antihistamines, and other NSAIDs), and herbal medication (including, but not limited
             to, herbal tea, St. John s Wort), within 14 days prior to study drug administration
             through the final follow-up visit, unless approved by the investigator.

        EXCLUSION CRITERIA:

          1. Presence of self-reported or medically documented significant medical condition
             including but not limited to:

               1. Chronic pulmonary disease (e.g., asthma, emphysema).

               2. Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure,
                  cardiac surgery, ischemic heart disease, known anatomic defects).

               3. Chronic medical conditions requiring close medical follow-up or hospitalization
                  during the past 5 years (e.g., insulin dependent diabetes mellitus, renal
                  dysfunction, hemoglobinopathies).

               4. Immunosuppression or ongoing malignancy.

               5. Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy,
                  stroke, seizures).

               6. Postinfectious or postvaccine neurological sequelae.

               7. Hyperlipidemia requiring medical therapy per current American College of
                  Cardiology (ACC) and American Heart Association (AHA) guidelines published in
                  2013.

          2. Have close or household (i.e., share the same apartment or house) high-risk contacts
             including but not limited to:

               1. Persons greater than or equal to 65 years of age.

               2. Children less than or equal to 5 years of age.

               3. Residents of nursing homes.

               4. Persons of any age with significant chronic medical conditions such as:

                    -  Chronic pulmonary disease (e.g., severe asthma, COPD).

                    -  Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart
                       failure, cardiac surgery, ischemic heart disease, known anatomic defects).

                    -  Contacts who required medical follow-up or hospitalization during the past 5
                       years because of chronic metabolic disease (e.g., insulin dependent diabetes
                       mellitus, renal dysfunction, hemoglobinopathies).

                    -  Immunosuppression or cancer.

                    -  Neurological and neurodevelopmental conditions (e.g., cerebral palsy,
                       epilepsy, stroke, seizures).

                    -  Individuals who are receiving long-term aspirin therapy.

                    -  Women who are pregnant or who are trying to become pregnant.

          3. Positive serology for hepatitis C virus antibody or hepatitis B surface antigen.

          4. Individual with body mass index (BMI) greater than or equal to 18 and greater than or
             equal to 35 or weight &gt; 114kg.

          5. Acute illness within 7 days of admission and inoculation with the challenge virus (Day
             -1).

          6. Complete blood count (CBC) with differential outside of the NIH Department of
             Laboratory Medicine (DLM) normal reference range and deemed clinically significant by
             the PI.

          7. Chemistries in the acute care, mineral, and/or hepatic panels, and/or any of the
             following: lactate dehydrogenase, uric acid, creatine kinase, and total protein
             outside of the NIH DLM normal reference range and deemed clinically significant by the
             PI.

          8. Amylase or Lipase outside of the NIH DLM normal reference range and deemed clinically
             significant by the PI.

          9. Urinalysis outside of the NIH DLM normal reference range and deemed clinically
             significant by the PI.

         10. Clinically significant abnormality as deemed by the PI on electrocardiogram.

         11. Clinically significant abnormality as deemed by the PI on echocardiographic (ECHO)
             testing.

         12. Clinically significant abnormality as deemed by the PI on the Pulmonary Function Test
             (PFT).

         13. Known allergy to treatments for influenza (including but not limited to oseltamivir,
             nonsteroidals).

         14. Known allergy to 2 or more classes of antibiotics (e.g., penicillins, cephalosporins,
             fluoroquinolones, or glycopeptides).

         15. Receipt of blood or blood products (including immunoglobulins) within 3 months prior
             to enrollment.

         16. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is
             greater) prior to enrollment.

         17. Receipt of any non-influenza-related unlicensed vaccine within 6 months prior to
             enrollment.

         18. Self-reported or known history of current alcoholism or drug abuse, or positive
             urine/serum test for drugs of abuse and/or ethanol (i.e., amphetamines, cocaine,
             benzodiazepines, opiates, or metabolites, but not tetrahydrocannabinol (THC) or
             metabolites).

         19. Self-reported or known history of psychiatric or psychological issues deemed by the PI
             to be a contraindication to protocol participation.

        19. Known close contact with anyone known to have influenza in the past 7 days.

        21. Known or suspected hypersensitivity to CR6261 or its excipients (sucrose, L-histidine,
        L-histidine monohydrochloride, polysorbate 20).

        22. History of a previous severe allergic reaction with generalized urticaria, angioedema,
        or anaphylaxis.

        23. Drinks more than 1200 mL (or 5 cups of 240 mL per cup) of tea/coffee/cocoa/cola or
        other caffeinated beverage per day more than 1 day per week in the 2 weeks before
        screening.

        24. Any condition or event that, in the judgment of the PI, is a contraindication to
        protocol participation or impairs the volunteer s ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Memoli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 30, 2018</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <results_first_submitted>December 19, 2019</results_first_submitted>
  <results_first_submitted_qc>January 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2020</results_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza A</keyword>
  <keyword>H1N1</keyword>
  <keyword>Challenge Model</keyword>
  <keyword>Human Immunoglobulin and H1N1</keyword>
  <keyword>Efficacy and Safety in H1N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02371668/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>104 participants signed consent and were enrolled on the protocol. 91 participants were inoculated and randomized. 13 participants did not meet criteria for influenza challenge at Day 0.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CR6261</title>
          <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator</title>
          <description>Placebo, 5% dextrose (D-glucose) water</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CR6261</title>
          <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
        </group>
        <group group_id="B2">
          <title>Placebo Comparator</title>
          <description>Placebo, 5% dextrose (D-glucose) water</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Viral Shedding</title>
        <description>Area under the curve (AUC) calculated from quantitative real-time RT-PCR for influenza A taken from 3 time per day nasal swab collection.</description>
        <time_frame>3 times a day for 10 days</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Viral Shedding</title>
          <description>Area under the curve (AUC) calculated from quantitative real-time RT-PCR for influenza A taken from 3 time per day nasal swab collection.</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>ViralLoad(log(copies/ml))per time(hours)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.56" lower_limit="8.00" upper_limit="209.68"/>
                    <measurement group_id="O2" value="25.53" lower_limit="5.00" upper_limit="159.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Influenza Infection</title>
        <description>Percentage of participants who experienced either viral shedding or symptoms + a four fold rise in convalescent HAI titer.</description>
        <time_frame>Evaluated daily for 10 days + 8 weeks convalescent follow up</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Influenza Infection</title>
          <description>Percentage of participants who experienced either viral shedding or symptoms + a four fold rise in convalescent HAI titer.</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Shedding</title>
        <description>Duration in days viral shedding was detected after influenza challenge</description>
        <time_frame>Evaluated for up to 2 months</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Shedding</title>
          <description>Duration in days viral shedding was detected after influenza challenge</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4989</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Symptoms</title>
        <description>Duration in days symptoms were experienced after influenza challenge</description>
        <time_frame>Evaluated for up to 2 months</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Symptoms</title>
          <description>Duration in days symptoms were experienced after influenza challenge</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1412</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mild to Moderate Influenza Disease</title>
        <description>Percentage of participants who experienced influenza symptoms and shedding</description>
        <time_frame>Evaluated daily for 10 days</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Mild to Moderate Influenza Disease</title>
          <description>Percentage of participants who experienced influenza symptoms and shedding</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.137</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptoms</title>
        <description>Number of unique influenza symptoms experienced after influenza challenge</description>
        <time_frame>Evaluated for up to 2 months</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptoms</title>
          <description>Number of unique influenza symptoms experienced after influenza challenge</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>Symptoms</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2445</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms</title>
        <description>Percentage of participants who experienced influenza symptoms</description>
        <time_frame>Evaluated daily for 10 days</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms</title>
          <description>Percentage of participants who experienced influenza symptoms</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total FLUPRO Score</title>
        <description>Objective symptoms score from patient directed FLUPRO questionnaire (inFLUenza Patient-Reported Outcome dairy) . The FLUPRO questionnaire uses a 5-point ordinal scale, with higher scores indicating a more frequent sign or symptom. Total scores can range from 0 (symptom free) to 4 (maximum severity of symptoms). Daily scores (Day 0 - Day 8) are averaged to calculate a total score for each participant, then calculated the median total FLUPRO score for each arm.</description>
        <time_frame>Evaluated from day 0 to day 8</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Total FLUPRO Score</title>
          <description>Objective symptoms score from patient directed FLUPRO questionnaire (inFLUenza Patient-Reported Outcome dairy) . The FLUPRO questionnaire uses a 5-point ordinal scale, with higher scores indicating a more frequent sign or symptom. Total scores can range from 0 (symptom free) to 4 (maximum severity of symptoms). Daily scores (Day 0 - Day 8) are averaged to calculate a total score for each participant, then calculated the median total FLUPRO score for each arm.</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" lower_limit="0.0125" upper_limit="0.08438"/>
                    <measurement group_id="O2" value="0.057" lower_limit="0.04063" upper_limit="0.08438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.230</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Shedding</title>
        <description>Percentage of participants who experienced influenza viral shedding</description>
        <time_frame>Evaluated daily for 10 days</time_frame>
        <population>All participants who were challenged with H1N1 and received CR6261</population>
        <group_list>
          <group group_id="O1">
            <title>CR6261</title>
            <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo, 5% dextrose (D-glucose) water</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Shedding</title>
          <description>Percentage of participants who experienced influenza viral shedding</description>
          <population>All participants who were challenged with H1N1 and received CR6261</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.646</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>70 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CR6261</title>
          <description>CR6261, Investigational monoclonal antibody against influenza A viruses</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator</title>
          <description>Placebo, 5% dextrose (D-glucose) water</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Oxygen saturation abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Memoli, Matthew</name_or_title>
      <organization>National Institute of Allergy and Infectious Diseases</organization>
      <phone>+1 301 443 5971</phone>
      <email>mm982v@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

